Weight-loss drug leaders engage in pricing war

Eli Lilly and Novo Nordisk are slashing prices to encourage more health plans to cover the medicine.

In partnership with

TODAY’S STORY

Americans want Ozempic and other weight loss drugs, but not everyone can afford them.

The $1,000-plus price tag on the branded versions of the drug has prompted millions of Americans to turn to lower-priced compounded versions and led many health plans to refuse coverage.

Eli Lilly and Novo Nordisk, the pharmaceutical companies behind the popular injections, are cutting prices to help those paying out of pocket and encourage more health plans to begin paying for the medicine:

  • Lilly is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399/month

  • Novo Nordisk confirmed that the price of Ozempic after discounts is down 40% since the drug’s launch

It’s still not a bargain, but if politicians get their way, prices will continue to decline in the coming months.

The price war for weight-loss drugs is just getting started.

Want SOC 2 compliance without the Security Theater?

  • Get the all-in-one platform for SOC 2

  • Build real-world security 💪

  • Penetration testing, compliance software, 3rd party audit, & vCISO

#SHORTS

OpenAI is nothing without the trust of consumers

@boringbusinesskieran

OpenAI is nothing without the TRUST of consumers // Make sure to follow me to keep up with the latest business stories and trends #busines... See more

PREVIOUS STORIES

To read the web version of previous stories, click here

If you have any comments or feedback, just respond to this email.

Thanks for reading,
Kieran & Justin Ryan